Business · 15/09/2020
FDA Requests Stakeholder Participation in Generic Drug User Fee Amendments Reauthorization
The FDA is seeking public input from patient advocacy groups, healthcare professionals, and scientific experts to ensure continuity in discussions with the regulated industry regarding the reauthorization of the Generic Drug User Fee Amendments of 2017.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →